Capital Group Global Equity Fund (LUX) C (USD)Register to Unlock Ratings |
Performance History | 30/04/2024 |
Growth of 1,000 (GBP) | Advanced Graph |
Fund | 12.4 | 16.4 | -4.6 | 12.0 | 5.0 | |
+/-Cat | 1.8 | -1.7 | 4.8 | -0.7 | -0.5 | |
+/-B’mrk | 0.2 | -3.3 | 3.2 | -3.2 | -1.5 | |
Category: Global Large-Cap Blend Equity | ||||||
Category Benchmark: Morningstar Global TME NR USD |
Key Stats | ||
NAV 24/05/2024 | USD 62.25 | |
Day Change | 0.47% | |
Morningstar Category™ | Global Large-Cap Blend Equity | |
ISIN | LU0114999708 | |
Fund Size (Mil) 24/05/2024 | USD 783.60 | |
Share Class Size (Mil) 24/05/2024 | EUR 448.82 | |
Max Initial Charge | - | |
Ongoing Charge 28/03/2024 | 0.13% |
Investment Objective: Capital Group Global Equity Fund (LUX) C (USD) |
Long-term capital growth through investment primarily in listed Equity, researched and selected on a world-wide basis. Unlisted securities may also be purchased, subject to the relevant provisions of the "General Investment Guidelines and Restrictions". |
Returns | |||||||||||||
|
Management | ||
Manager Name Start Date | ||
Philip Winston 22/01/2020 | ||
William Robbins 22/01/2020 | ||
Click here to see others | ||
Inception Date 03/10/2000 |
Advertisement |
Category Benchmark | |
Fund Benchmark | Morningstar Benchmark |
MSCI World NR USD | Morningstar Global TME NR USD |
Target Market | ||||||||||||||||||||
|
Portfolio Profile for Capital Group Global Equity Fund (LUX) C (USD) | 30/04/2024 |
|
|
Top 5 Holdings | Sector | % |
Novo Nordisk A/S Class B | Healthcare | 3.23 |
Broadcom Inc | Technology | 2.79 |
Microsoft Corp | Technology | 2.33 |
Safran SA | Industrials | 2.07 |
AstraZeneca PLC | Healthcare | 2.05 |
Increase Decrease New since last portfolio | ||
Capital Group Global Equity Fund (LUX) C (USD) |